TABLE 2.
Pharmacodynamic parameters estimated for DOX, SFB, and 5-FU as combined with let-7c or control MSA in the inhibition of Huh7 cell viability
| MSA | Let-7c | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.0 nM | 2.5 nM | 1.0 nM | 2.5 nM | ||||||||||
| EC50 | DOX (nM) | 150.8 | ± | 1.2 | 69.9 | ± | 1.6 | 117.8 | ± | 1.2 | 120.9 | ± | 1.4 |
| SFB (µM) | 6.4 | ± | 1.0 | 5.4 | ± | 1.1 | 5.9 | ± | 1.1 | 3.9 | ± | 1.4 | |
| 5-FU (µM) | 113.9 | ± | 1.5 | 121.6 | ± | 1.4 | 23.8 | ± | 1.3* | 0.2 | ± | 14.9* | |
| Emin | DOX (nM) | 17.9 | ± | 1.9 | 21.7 | ± | 4.3 | 26.2 | ± | 2.0* | 44.1 | ± | 2.1* |
| SFB (µM) | 15.9 | ± | 1.4 | 32.3 | ± | 1.8 | 32.9 | ± | 1.3* | 54.1 | ± | 3.6* | |
| 5-FU (µM) | 1.3 | ± | 4.0 | 0.00 | ± | 4.47 | 3.2 | ± | 2.4 | 0.00 | ± | 31.7 | |
| Hill slope | DOX | 0.7 | ± | 0.1 | 0.5 | ± | 0.1 | 0.7 | ± | 0.1 | 0.6 | ± | 0.1 |
| SFB | 2.4 | ± | 0.3 | 2.3 | ± | 0.4 | 2.3 | ± | 0.3 | 1.1 | ± | 0.4 | |
| 5-FU | 0.5 | ± | 0.1 | 0.6 | ± | 0.1 | 0.4 | ± | 0.0 | 0.2 | ± | 0.1 | |
| R2 | DOX | 0.98 | 0.93 | 0.97 | 0.95 | ||||||||
| SFB | 0.99 | 0.97 | 0.99 | 0.86 | |||||||||
| 5-FU | 0.92 | 0.94 | 0.99 | 0.90 | |||||||||
*
P < 0.05 compared with corresponding MSA control treatment.